Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$20.75
+1.5%
$18.04
$13.53
$35.25
$2.09B2.071.56 million shs2.18 million shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$46.46
-1.7%
$46.30
$20.14
$53.42
$5.76B1.442.17 million shs1.77 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$35.17
-1.9%
$33.69
$27.12
$60.90
$2.11B2.41962,090 shs624,000 shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$23.51
-2.9%
$27.15
$19.73
$47.32
$1.84B2.07917,401 shs1.61 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.00%-1.94%+23.81%+13.76%-20.01%
Guardant Health, Inc. stock logo
GH
Guardant Health
0.00%-7.54%-5.45%+9.04%+51.09%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-7.52%+1.53%+1.77%-34.75%
Veracyte, Inc. stock logo
VCYT
Veracyte
0.00%-13.18%-10.91%-23.17%+1.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
1.998 of 5 stars
3.50.00.00.02.12.50.6
Guardant Health, Inc. stock logo
GH
Guardant Health
4.4592 of 5 stars
3.53.00.04.43.12.50.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.3208 of 5 stars
3.45.00.04.42.20.80.6
Veracyte, Inc. stock logo
VCYT
Veracyte
3.7663 of 5 stars
3.41.00.04.33.80.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.00
Buy$48.75134.94% Upside
Guardant Health, Inc. stock logo
GH
Guardant Health
3.05
Buy$54.4517.20% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4043.30% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.70
Moderate Buy$40.9073.97% Upside

Current Analyst Ratings Breakdown

Latest VCYT, BEAM, GH, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/13/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.00
5/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $42.00
5/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $41.00
5/7/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $55.00
5/7/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.00
5/7/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.00
5/6/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$63.52M32.85N/AN/A$8.86 per share2.34
Guardant Health, Inc. stock logo
GH
Guardant Health
$739.02M7.79N/AN/A($1.13) per share-41.12
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.73N/AN/A$8.07 per share4.36
Veracyte, Inc. stock logo
VCYT
Veracyte
$445.76M4.13$1.04 per share22.67$15.17 per share1.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)
Guardant Health, Inc. stock logo
GH
Guardant Health
-$436.37M-$3.39N/AN/AN/A-53.82%N/A-26.77%7/30/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/4/2025 (Confirmed)
Veracyte, Inc. stock logo
VCYT
Veracyte
$24.14M$0.4157.3432.65N/A7.13%6.14%5.60%8/6/2025 (Estimated)

Latest VCYT, BEAM, GH, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.31N/AN/AN/A$120.90 millionN/A
8/5/2025Q2 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.04N/AN/AN/A$13.29 millionN/A
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
7/30/2025Q2 2025
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.52N/AN/AN/A$211.19 millionN/A
5/6/2025Q1 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
4/30/2025Q1 2025
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
8.81
8.81
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
4.11
3.76
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
5.10
4.78

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.50%
Guardant Health, Inc. stock logo
GH
Guardant Health
6.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510100.56 million97.04 millionOptionable
Guardant Health, Inc. stock logo
GH
Guardant Health
2,021123.89 million116.33 millionNot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79078.32 million77.22 millionOptionable

Recent News About These Companies

Veracyte (NASDAQ:VCYT) Trading Down 5.9% - Here's Why
Veracyte Inc (VCYT) Stock Price Down 4.21% on Jul 18
Veracyte, Inc. (VCYT) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$20.75 +0.30 (+1.47%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$21.24 +0.49 (+2.36%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Guardant Health stock logo

Guardant Health NASDAQ:GH

$46.46 -0.82 (-1.73%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$46.88 +0.42 (+0.91%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$35.17 -0.68 (-1.90%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$35.14 -0.03 (-0.09%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$23.51 -0.71 (-2.93%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$23.39 -0.12 (-0.51%)
As of 05:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.